Telomir Pharmaceuticals, Inc. 8-K

What Happened
Telomir Pharmaceuticals (NASDAQ: TELO) filed an 8-K (Item 8.01) on January 5, 2026, reporting results from a completed preclinical study showing Telomir‑1 (Zn‑Telomir) significantly reduced primary tumor growth and, in some models, cancer cell spread in zebrafish xenograft models of triple‑negative breast cancer (TNBC). The study, conducted with BioReperia using its ZTX® ONCOLEADS platform, tested Telomir‑1 alone and combined with the chemotherapy paclitaxel across three distinct human TNBC cell‑line models.

Key Details

• Telomir‑1 produced statistically significant reductions in primary tumor growth in two aggressive TNBC models; in one of these (paclitaxel‑nonresponsive) Telomir‑1 also reduced cancer cell spread at specific concentrations.
• In the other responsive model, Telomir‑1 monotherapy matched paclitaxel’s tumor inhibition and the combination was more inhibitory than either agent alone.
• A third model, representing broadly treatment‑resistant TNBC, showed no statistically significant response to Telomir‑1 or paclitaxel. Estimated prevalence: responsive model types ~40–60% of TNBC; resistant type ~15–25%, per published subtype analyses cited by the company.
• The company is continuing IND‑enabling activities and refining patient‑selection strategies based on these preclinical results.

Why It Matters
These data provide early preclinical evidence that Telomir‑1 can inhibit tumor growth and, in some tumor types, reduce metastatic spread—information that can help Telomir prioritize patient populations and trial design as it advances toward IND filing and clinical studies. For investors, positive preclinical results can be a developmental milestone, but they are not proof of safety or efficacy in humans; further IND‑enabling work and clinical trials are still required.